Physician profile
Shelby E Calloway
NPI 1295272714
$16,275.29
in general payments reported to CMS, 2019-2025
65 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,186 · 2022: $3,388 · 2023: $2,786 · 2024: $4,185 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,701.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,201.97 | 2021-2025 | |
| Ucb, INC. | $1,133.34 | 2021-2025 | Fintepla, Briviact, Rystiggo |
| Biogen, INC. | $881.71 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Sk Life Science, INC. | $871.00 | 2021-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $772.61 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $754.29 | 2021-2025 | Acthar |
| Lundbeck LLC | $563.48 | 2022-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $560.55 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $494.81 | 2023-2025 | |
| Neurelis, INC. | $483.71 | 2021-2025 | Valtoco |
| Eisai INC. | $483.50 | 2021-2025 | |
| Argenx US, INC. | $354.87 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $338.96 | 2021-2025 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $321.14 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $320.20 | 2022-2025 | Dysport, Onivyde |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $308.90 | 2021-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $296.16 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $287.96 | 2022-2025 | Ultomiris |
| Kyowa Kirin, INC. | $267.96 | 2021-2024 | Nourianz |
| Genentech USA, INC. | $267.21 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Evrysdi |
| Csl Behring | $262.75 | 2021-2025 | Hizentra |
| Lilly USA, LLC | $257.20 | 2024-2025 | Kisunla, Amyvid |
| Catalyst Pharmaceuticals, INC. | $241.58 | 2023-2025 | Fycompa, Firdapse |
| Takeda Pharmaceuticals U.S.A., INC. | $211.24 | 2023-2025 | Hyqvia |
| Averitas Pharma INC. | $201.39 | 2024-2025 | Qutenza |
| Amgen INC. | $190.82 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $187.14 | 2021-2025 | Xeomin, Inbrija |
| Sunovion Pharmaceuticals INC. | $186.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.50 | 2022 | |
| Livanova USA, INC. | $180.27 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $169.26 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $167.16 | 2023-2024 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $142.85 | 2021 | |
| Acadia Pharmaceuticals INC | $134.60 | 2021-2025 | Daybue |
| Otsuka America Pharmaceutical, INC. | $131.79 | 2023-2025 | Rexulti |
| Celgene Corporation | $126.37 | 2023-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $117.72 | 2021-2023 | Ponvory |
| Grifols USA, LLC | $112.45 | 2023-2025 | Gamunex-C |
| Boston Scientific Corporation | $99.67 | 2021-2024 | Watchman Flx |
| Horizon Therapeutics Plc | $82.95 | 2021-2023 | Uplizna |
| Tanabe Pharma America, INC. | $79.68 | 2021-2025 | Radicava |
| Aquestive Therapeutics, INC. | $74.33 | 2022 | |
| Sumitomo Pharma America, INC. | $68.34 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $58.81 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $54.70 | 2024-2025 | Wainua |
| Harmony Biosciences LLC | $45.98 | 2023 | Wakix |
| Banner Life Sciences, LLC | $45.55 | 2022 | |
| Alnylam Pharmaceuticals INC. | $43.80 | 2021-2023 | Onpattro |
| Genzyme Corporation | $43.37 | 2023-2025 | |
| Acorda Therapeutics, INC | $42.46 | 2021-2023 | Inbrija |
| Sarepta Therapeutics, INC. | $39.32 | 2023 | Exondys 51 |
| Avion Pharmaceuticals | $39.09 | 2022 | |
| Adamas Pharmaceuticals, INC. | $38.94 | 2021 | |
| Janssen Biotech, INC. | $38.54 | 2025 | |
| Sandoz INC. | $27.69 | 2024 | |
| Immedica Pharma US, INC. | $24.76 | 2025 | Ztalmy |
| Hospira, INC. | $23.98 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $23.47 | 2023 | Relyvrio |
| Azurity Pharmaceuticals, INC. | $20.46 | 2023 | Eprontia |
| Ani Pharmaceuticals, INC. | $19.12 | 2023 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $16.30 | 2023 | Trudhesa |
| Corium, LLC | $15.12 | 2023 | Azstarys |
| Insightec,INC | $13.72 | 2024 | Exablate |
| Amneal Pharmaceuticals LLC | $13.58 | 2025 | Crexont |
| Medtronic, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby Calloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.